LFA-3

出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/12/10 15:31:08」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Results of a Randomized Phase I Gene Therapy Clinical Trial of Non-oncolytic Fowlpox Viruses Encoding T cell Co-stimulatory Molecules.
  • Kaufman HL, Kim DW, Kim-Schulze S, Deraffele G, Joagoda MC, Broucek J, Zloza A.Author information Rutgers University, Surgery, 195 Little Albany Street, New Brunswick, New Jersey, United States, 08901, 917-822-7778, 732-235-6797 ; howardkaufman6@gmail.com.AbstractOncolytic viruses have shown promise as gene delivery vehicles in the treatment of cancer; however, their efficacy may be inhibited by the induction of anti-viral antibody titers. Fowlpox virus is a non-replicating and non-oncolytic vector that has been associated with lesser humoral but greater cell-mediated immunity in animal tumor models. To test whether fowlpox virus gene therapy is safe and can elicit immune responses in cancer patients, we conducted a randomized phase I clinical trial of two recombinant fowlpox viruses encoding human B7.1 or a triad of co-stimulatory molecules (B7.1, ICAM-1, and LFA-3; TRICOM). Twelve patients (10 melanoma and two colon adenocarcinoma) enrolled in the trial and were randomized to rF-B7.1 or rF-TRICOM administered in a dose escalation manner (~3.7 x 107 or ~3.7 x 108 PFU) by intra-lesional injection every four weeks. The therapy was well tolerated with only four patients experiencing grade 1 fever or injection site pain and there were no serious adverse events. All patients developed anti-viral antibody titers following vector delivery and post-treatment anti-CEA antibody titers were detected in the two patients with colon cancer. All patients developed CD8+ T cell responses against fowlpox virus but few responses against defined tumor-associated antigens were observed. To our knowledge, this is the first clinical trial of direct (intra-tumoral) gene therapy with a non-oncolytic fowlpox virus. Treatment was well tolerated in patients with metastatic cancer and all subjects exhibited anti-viral antibody responses but limited tumor-specific T cell responses were detected. Non-oncolytic fowlpox viruses are safe and induce limited T cell responses in cancer patients. Further development may include prime-boost strategies utilizing oncolytic viruses for initial priming.
  • Human gene therapy.Hum Gene Ther.2014 Feb 2. [Epub ahead of print]
  • Oncolytic viruses have shown promise as gene delivery vehicles in the treatment of cancer; however, their efficacy may be inhibited by the induction of anti-viral antibody titers. Fowlpox virus is a non-replicating and non-oncolytic vector that has been associated with lesser humoral but greater cel
  • PMID 24484178
  • Increased numbers and functional activity of CD56+ T cells in healthy cytomegalovirus positive subjects.
  • Almehmadi M, Flanagan BF, Khan N, Alomar S, Christmas SE.Author information Department of Clinical Infection, Microbiology and Immunology, Institute of Infection & Global Health, University of Liverpool, Liverpool, UK.AbstractHuman T cells expressing CD56 are capable of tumour cell lysis following activation with IL-2 but their role in viral immunity has been less well studied. Proportions of CD56+ T cells were found to be highly significantly increased in CMV seropositive (CMV+) compared to seronegative (CMV-) healthy subjects (9.1±1.5% vs. 3.7±1.0%; p<0.0001). Proportions of CD56+ T cells expressing CD28, CD62L, CD127, CD161 and CCR7 were significantly lower in CMV+ than CMV- subjects but that those expressing CD4, CD8, CD45RO, CD57, CD58, CD94 and NKG2C were significantly increased (p<0.05), some having the phenotype of TEM cells. Levels of proinflammatory cytokines and CD107a were significantly higher in CD56+ T cells from CMV+ than CMV- subjects following stimulation with CMV antigens. This also resulted in higher levels of proliferation in CD56+ T cells from CMV+ than CMV- subjects. Using Class I HLA pentamers, it was found that CD56+ T cells from CMV+ subjects contained similar proportions of antigen-specific CD8+ T cells to CD56- T cells in donors of several different HLA types. These differences may reflect expansion and enhanced functional activity of CMV-specific CD56+ memory T cells. In view of the link between CD56 expression and T cell cytotoxic function, this strongly implicates CD56+ T cells as being an important component of the cytotoxic T cell response to CMV in healthy carriers. This article is protected by copyright. All rights reserved.
  • Immunology.Immunology.2014 Jan 16. doi: 10.1111/imm.12250. [Epub ahead of print]
  • Human T cells expressing CD56 are capable of tumour cell lysis following activation with IL-2 but their role in viral immunity has been less well studied. Proportions of CD56+ T cells were found to be highly significantly increased in CMV seropositive (CMV+) compared to seronegative (CMV-) healthy s
  • PMID 24433347

和文文献

  • 次世代の生物学的製剤(第10回)アレファセプト
  • 梅原 久範
  • 分子リウマチ治療 3(3), 144-148, 2010-08-00
  • NAID 40017238659
  • Preparation of a Lemon Flavonoid Aglycone and its Suppressive Effect on the Susceptibility of LDL to Oxidation Following Human Ingestion
  • MIYAKE Yoshiaki,SAKURAI Chika,USUDA Mika,HIRAMITSU Masanori,KONDO Kazuo
  • Food science and technology research 15(1), 83-88, 2009-01-01
  • … It is indicated to have low bioavailability compared with lemon flavonoid aglycone (LFA), which predominantly contains eriodictyol. … This study attempted to prepare LFA which has high bioavailability, using enzymes that are commonly used in the citrus industry, such as cellulase, naringinase, hesperidinase, and pectinase. … LFA containing the highest amount of eriodictyol (19.4%) was prepared with naringinase, a debittering enzyme for citrus juice. …
  • NAID 10025348617
  • Enhanced Fc-Dependent Cellular Cytotoxicity of Fc Fusion Proteins Derived from TNF Receptor II and LFA-3 by Fucose Removal from Asn-Linked Oligosaccharides
  • Shoji-Hosaka Emi,Kobayashi Yukari,Wakitani Masako [他],UCHIDA Kazuhisa,NIWA Rinpei,NAKAMURA Kazuyasu,SHITARA Kenya
  • The journal of biochemistry 140(6), 777-783, 2006-12-01
  • NAID 10018840363

関連リンク

Lexus LFA vs Nissan GTR (2012) vs 911 GT2 RS vs Corvette ZR1 vs RSD Ferrari 430 F1 ... 緊急走行!!逮捕の瞬間!!警視庁 白バイ 車ガラス破壊の大捕物!!東京 市ヶ谷 2013.11.7 POLICE motor cycle Arrest break the ...
レクサス LFA 製作記3 2011.06.16(木曜日) 前回までで塗装がほぼ終了しましたので、今日はばんばん組み上げていきたいと思います。 こうしてザッと並べてみると、パーツ数が多いですね。しかも、これらは内装と足回りのパーツ のみ ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元接着分子」「T細胞」「CD2」「CD58
関連記事L」「LF」「LFA

接着分子」

  [★]

adhesion molecule
接着因子

接着分子のファミリー

白血球の相互作用に関与している接着分子 (IMM.87)

グループ名 機能 名称 別名 組織分布 リガンド
セレクチン 炭化水素鎖に結合。
白血球-内皮細胞の反応を開始
P-selectin PADGEN CD62P 活性化した内皮細胞、活性化した血小板 PSGL-1, sialyl-Lewisx
E-selectin ELAM-1 CD62E 活性化した内皮細胞 sialyl-Lewisx
インテグリン CAMや細胞外マトリックスに結合。
強い結合
LFA-1 αL:β2 CD11a:CD18 単球、T細胞、マクロファージ、好中球、樹状細胞 ICAMs
CR3, Mac-1 αM:β2 CD11b:CD18 好中球、単球、マクロファージ ICAM-1, iC3b, fibrinogen
CR4, p150.95 αX:β2 CD11c:CD18 樹状細胞、マクロファージ、好中球 iC3b
VLA-5 α5:β1 CD49d:CD29 単球、マクロファージ fibronectin
免疫グロブリンスーパーファミリー 細胞結合で様々に働く。
インテグリンの基質
ICAM-1   CD54 活性化した内皮細胞 LFA-1, MAC1
ICAM-2   CD102 非活性化状態の内皮細胞、樹状細胞 LFA-1
VCAM-1   CD106 活性化した内皮細胞 VLA-4
PECAM   CD31 活性化した白血球、内皮細胞間の結合 CD31

白血球の相互作用に関与している免疫グロブリンスーパーファミリーの接着分子 (IMM.329)

名称 分布組織 リガンド
CD2 LFA-2 T細胞 LFA-1 CD53
ICAM-1 CD54 活性化した血管、リンパ球、樹状細胞 LFA-1, Mac-1  
ICAM-2 CD102 非活性化状態の血管 LFA-1  
ICAM-3 CD50 Naive T cells DC-SIGN, LFA-1  
LFA-3 CD58 リンパ球、APC CD2  
VCAM-1 CD106 活性化した内皮細胞 VLA-4  
-接着分子
-細胞接着分子
-カドヘリン


T細胞」

  [★]

T cell
Tリンパ球T lymphocyte
TCRB細胞MHC
  • 図:IMM.315(T細胞の成熟)
  • 胸腺で成熟したT細胞は血流によって移動し、リンパ節の傍皮質白脾髄のリンパ性動脈周囲鞘、パイエル板の傍濾胞域に集まる(人間の正常構造と機能 VIIA血管・免疫 p.28)

種類

  1. ヘルパーT細胞(Th細胞)
  2. キラーT細胞(Tc細胞)
  3. サプレッサーT細胞(Treg細胞)

T細胞の抗原認識 (SP.248)

  CD TCRが抗原と共に認識する分子 認識する細胞
Tc細胞 CD8 MHCクラスI 感染細胞
Th細胞 CD4 MHCクラスII 抗原提示細胞

CD4+ T細胞のサイトカイン放出とその原因

DCが認識する外来異物 DCが分泌する物質 DCに反応する細胞 この細胞が分泌する
サイトカイン
NK系の細胞が放出した
サイトカインに反応するTh細胞
Th細胞が分泌するサイトカイン
ウイルス、一部の細菌 IL-12 NK細胞(IL-12による) INF-γ Th1 IL-2, IFN-γ, TNF-β
原虫など   NKT細胞 IL-4 Th2 IL-4, IL-13, IL-5

Th細胞活性化と接着分子

  抗原提示細胞 Th細胞
主シグナル MHC classII TCR, CD3
CD4
副シグナル B7{B7-1(CD80)/B7-2(CD86)} CD28
VCAM-1(CD106) VLA-4
ICAM-1 LFA-1
LFA-3(CD58) CD2


CD2」

  [★]

Leucine-5, SRBC receptor, LFA-2
CD


発現細胞

分子量

  • 45-58

機能

  • 接着分子、CD58(LFA-3)に結合。細胞内部でLckに結合し、T細胞を活性化
  • リンパ球が抗原提示細胞と相互作用するのに重要 (IMM.343)

別名

ファミリー

  • immunoglobulin



CD58」

  [★]

LFA-3


Leukocyte function antigen
LFA-3


L」

  [★]

WordNet   license wordnet

「the 12th letter of the Roman alphabet」
l

PrepTutorEJDIC   license prepejdic

「lira(イタリアの貨幣単位リラ)」

LF」

  [★]

PrepTutorEJDIC   license prepejdic

「low frequency」


LFA」

  [★] リンパ球機能関連抗原


"http://meddic.jp/LFA-3" より作成


★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡